* ENDRA Life Sciences Inc NDRA.OQ reported a quarterly
adjusted
loss of 43 cents per share for the quarter ended in June. The
lone analyst forecast for the quarter was for a loss of 55 cents
per share.
* Reported revenue was zero; analysts expected zero.
* ENDRA Life Sciences Inc's reported EPS for the quarter was
a
loss of 43 cents.
* The mean earnings estimate of analysts had risen by
about 37.9%
in the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
* ENDRA Life Sciences Inc shares had fallen by 7.1% this
quarter and lost 68.1% so far this year.
* The company reported a quarterly loss of $2.56 million.
* Wall Street's median 12-month price target for ENDRA Life
Sciences Inc is $20.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from LSEG Refinitiv data
August 14 at 09:39 p.m. UTC. All figures in US dollars unless
otherwise stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2023 -0.55 -0.43 Beat
Mar. 31 2023 -1.04 -0.93 Beat
Dec. 31 2022 -0.90 -0.96 Missed
Sep. 30 2022 -1.10 -1.00 Beat